JOHNSON & JOHNSON JNJ

Johnson & Johnson announced the planned separation of its Orthopaedics business, DePuy Synthes, to further sharpen its focus on high-growth, high-margin markets. This move is part of a continuous portfolio optimization strategy aimed at accelerating growth in Innovative Medicine and MedTech. The new DePuy Synthes will be the largest, most comprehensive orthopaedics company, addressing a market exceeding $50 billion, and is expected to benefit from a more focused business model and enhanced flexibility. The separation is targeted for completion within 18 to 24 months, with a spin-off being the prioritized tax-free option.

The Innovative Medicine segment delivered 5.3% operational sales growth, overcoming a significant 1,070 basis point headwind from STELARA's loss of exclusivity. This growth was fueled by double-digit increases across 11 brands, including DARZALEX (19.9%), CARVYKTI (81.4%), and TREMFYA (40.1%). New launches like INLEXZO for bladder cancer, with a projected $5 billion annual peak sales, and the combination of RYBREVANT plus LAZCLUZE for lung cancer, also a $5 billion peak sales asset, are expected to drive future growth. The company also highlighted the strong performance of SPRAVATO (60.8%) in neuroscience and the recent acquisition of CAPLYTA.

MedTech operational sales accelerated to 5.6%, with strong performance across Cardiovascular, Surgery, and Vision. Cardiovascular sales increased by approximately 12%, driven by Shockwave (20% growth) and Abiomed (15% growth). Electrophysiology delivered close to 10% growth, bolstered by VARIPULSE. Surgical Vision grew 13.8% due to new product innovations like TECNIS PureSee. The company's strategy is to concentrate on these high-growth areas, with the Orthopaedics spin-off expected to improve MedTech's top-line revenue growth and operating margin by at least 75 basis points.

J&J is advancing its pipeline with significant regulatory milestones. FDA approval for INLEXZO in bladder cancer was received, and the company anticipates FDA approval for subcutaneous RYBREVANT and CAPLYTA in adjunctive major depressive disorder. Icotrokinra, an oral peptide for plaque psoriasis, was submitted to the FDA in July, with Phase II data for ulcerative colitis already presented and a 2026 approval anticipated. In MedTech, the OTTAVA robotic surgical system is expected to have an FDA de novo submission in early 2026, and new product launches like Shockwave C2 Aero and TECNIS PureSee are planned for FY26.

The company generated $14 billion in free cash flow through the first 9 months of the year and ended Q3 with $19 billion in cash and marketable securities. Management emphasized a disciplined capital allocation strategy, prioritizing investment in its pipeline and portfolio. They explicitly stated that large M&A is not necessary to meet the high end of their growth targets, given the momentum of the current portfolio and pipeline. The company continues to pursue opportunistic, high-value smaller deals, citing 60 such deals in the last 18 months, which have led to assets like INLEXZO and icotrokinra.

Johnson & Johnson reiterated its commitment to investing $55 billion in U.S.-based innovation and manufacturing over the next four years. This includes breaking ground at its Wilson, North Carolina facility and a $2 billion commitment to a new manufacturing facility at FUJIFILM's biopharmaceutical site in Holly Springs. The company believes U.S. tax policy has enabled it to increase its manufacturing footprint in the U.S., where it has more facilities than in any other country. The increase in the effective tax rate to 31.2% was largely due to the One Big Beautiful Bill Act.